AstraZeneca's neurofibromatosis type 1 drug candidate selumetinib received orphan status from the FDA. The company has ongoing Phase I and II trials of the drug in pediatric patients with NF1, with results from the Phase II study anticipated later this year.
FDA orphan status granted to AZ's neurofibromatosis type 1 drug
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.